Recent Company News

• 08:09 PM ET May 18, 2026
  

  Alterity Therapeutics delivers presentations related to development program in multiple system atrophy (A$0.01, 0.00)

• 07:41 PM ET May 10, 2026
  

  Alterity Therapeutics notes peer-reviewed study of bioMUSE published in NeuroImage demonstrates utility of quantitative MRI as a biomarker for MSA (A$0.01, 0.00)

• 07:31 AM ET May 07, 2026
  

  Alterity Therapeutics to present results from study of ATH434 in MSA using CSF NfL as a covariate at MDSANZ Scientific Meeting (A$0.01, 0.00)

• 09:42 PM ET May 03, 2026
  

  StreetAccount Summary - Australia unusual volume traders

• 09:51 PM ET Apr 29, 2026
  

  Alterity Therapeutics to undertake 1-for-50 share consolidation (A$0.01, 0.00)

• 07:56 PM ET Apr 29, 2026
  

  Alterity Therapeutics reports Q3 net cash from / (used in) operating activities (A$4.7M) - Appendix 4C (A$0.01, 0.00)

• 02:38 PM ET Apr 28, 2026
  

  Transcript Intelligence: Alterity Therapeutics Investor Meeting - Key Opinion Leader

• 07:03 PM ET Apr 26, 2026
  

  Alterity Therapeutics receives positive FDA feedback following second type C meeting on ATH434 phase 3 program in MSA (A$0.01, 0.00)

• 02:26 PM ET Apr 24, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 26-Apr